Main content

Kidney and Pancreas Transplant Program

Kidney and Pancreas Transplant ProgramOpens new window | Adult Clinical Trials Main Page

Further protocol information can be found on the links below at ClinicalTrials.gov

Active Trials

Title: Controlled, Randomized, Prospective, Double-blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation
Description: I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation
Investigator: Ram Peddi, MD
Eligibility: Adult recipients of an expanded criteria donor (ECD) kidney that has been preserved by cold storage, or a standard criteria donor kidney that has been preserved by cold storage for at least 26 hours prior to transplant
Status: Active and open to enrollment
Contact: Jennifer Wilson, 415-600-1155, Email: WilsonJX@cpmcri.org about Study Quark

Title: A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de novo Kidney Transplantation
Description: A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
Investigator: Ram Peddi, MD
Eligibility: De Novo Kidney transplant recipients, 18-65, who will not receive antibody induction therapy (e.g., thymoglobulin, basiliximab, daclizumab, OKT3, alemtuzumab) at the time of transplant
Status: Active and open to enrollment
Contact: Jennifer Wilson, 415-600-1155, Email: WilsonJX@cpmcri.org about Study Astellas 0103

Title: A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing the Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to CellCept® (Mycophenolate Mofetil) With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients
Description: Non-inferiority Study of the Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Patients
Investigator: Ram Peddi, MD
Eligibility: Male or female renal recipients 18-70 years of age undergoing kidney transplantation, either primary or re-transplant
Status: Active and open to enrollment
Contact: Jennifer Wilson, 415-600-1155, Email: WilsonJX@cpmcri.org about Study CRAD001AUS92

Title: Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant
Description: Double-Blind,Double-Dummy,Effic/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx (LCPTacro3002)
Investigator: Ram Peddi, MD
Eligibility: Male or female renal recipients undergoing kidney transplantation, either primary or re-transplant
Status: Coming Soon
Contact: Nestor Mena, 415-600-1744, Email: MenaNZ@cpmcri.org about Study LCP-Tacro-3002

Title: Planned Transition To Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy In Renal Allograft Recipients
Description: Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
Investigator: Ram Peddi, MD
Eligibility: Renal Transplant Recepients 18 years and greater
Status: Active and open to enrollment
Contact: Nestor Mena, 415-600-1744, Email: MenaNZ@cpmcri.org about Study Wyeth 4500

Title: A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus
Description: Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
Investigator: Parul Patel, MD
Eligibility: Kidney transplant recipients with well controlled blood pressure and who are currently taking either tacrolimus or cyclosporine to prevent rejection of transplanted kidney
Status: Active and open to enrollment
Contact: Jennifer Wilson, 415-600-1155, Email: WilsonJX@cpmcri.org about Study Wyeth 4439

Title: A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients
Description: Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
Investigator: Ram Peddi, MD
Eligibility: Subjects 18 to 70 years of age who are first time renal tranplant recepients
Status: Active but closed to enrollment
Contact: Jennifer Wilson, 415-600-1155, Email: WilsonJX@cpmcri.org about Study JAK3-1021

Title: Phase 2, Multicenter, Open-Label, Active Comparator-Controlled, Extension Trial To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 In Renal Allograft Recipients
Description: Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
Investigator: Ram Peddi, MD
Eligibility: Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
Status: Active but closed to enrollment
Contact: Jennifer Wilson, 415-600-1155, Email: WilsonJX@cpmcri.org about Study JAK3-1050

Title: A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy
Description: Cidofovir in Renal Transplant Recipients With BKVN
Investigator: Ram Peddi, MD
Eligibility: Kidney transplant recipients who have been diagnosed with BK Virus Nephropathy
Status: Closed to enrollment
Contact: Jennifer Wilson, 415-600-1155, Email: WilsonJX@cpmcri.org about Study CASG 209